biostudies-literatureDorfel DEuropean Social FundWilhelm Sander-StiftungDeutsche Krebshilfe775-783https://www.ebi.ac.uk/biostudies/studies/S-EPMC11028318biostudies-literatureUnknown67(5)In chronic myeloid leukemia (CML), the translocation t(9;22) results in the fusion protein BCR-ABL (breakpoint cluster region-abelson murine leukemia), a tyrosine kinase mediating oncogenic signaling which is successfully targeted by treatment with BCR-ABL inhibitors like imatinib. However, BCR-ABL inhibitors may also affect antitumor immunity. For instance, it was reported that imatinib impairs the function of dendritic cells (DCs) that play a central role in initiating and sustaining T cell responses. Meanwhile, second generation BCR-ABL inhibitors like nilotinib, which inhibits BCR-ABL with enhanced potency have become standard of treatment, at least in patients with BCR-ABL kinase domain mutations. In this study we analyzed the influence of therapeutic concentrations of nilotinib on huCancer immunology, immunotherapy : CIIThe BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.PMC110283181090462013.148.1Kopp HGGeiger JMaurer SRittig SMLechner CJGutknecht MSalih JSalih HRDorfel DGrunebach FFunk TJoas SKropp KNMuller MRfalseThe BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.In chronic myeloid leukemia (CML), the translocation t(9;22) results in the fusion protein BCR-ABL (breakpoint cluster region-abelson murine leukemia), a tyrosine kinase mediating oncogenic signaling which is successfully targeted by treatment with BCR-ABL inhibitors like imatinib. However, BCR-ABL inhibitors may also affect antitumor immunity. For instance, it was reported that imatinib impairs the function of dendritic cells (DCs) that play a central role in initiating and sustaining T cell responses. Meanwhile, second generation BCR-ABL inhibitors like nilotinib, which inhibits BCR-ABL with enhanced potency have become standard of treatment, at least in patients with BCR-ABL kinase domain mutations. In this study we analyzed the influence of therapeutic concentrations of nilotinib on hu2018-01-01T00:00:00Z2018 May2026-06-01T21:54:43.972Z2025-04-06T03:15:21.014ZS-EPMC110283182946836310.1007/s00262-018-2129-9